Selected research
Market Structure
Global Etoposide Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Etoposide market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Etoposide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Etoposide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Etoposide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Etoposide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Etoposide include Teva Pharmaceutical, Qilu Antibiotics, Mylan, China Resources Double Crane Pharmaceutical, Shyndec Pharmaceutical, Nippon Kayaku, KPC Pharmaceuticals, Gansu Fuzheng and Accord Healthcare, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Etoposide market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Etoposide and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Etoposide sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Etoposide market size, projected growth trends, production technologies, key applications, and end-use industries.
Etoposide Segment by Company
Teva Pharmaceutical
Qilu Antibiotics
Mylan
China Resources Double Crane Pharmaceutical
Shyndec Pharmaceutical
Nippon Kayaku
KPC Pharmaceuticals
Gansu Fuzheng
Accord Healthcare
Etoposide Segment by Type
Etoposide for Injection
Etoposide for Oral Use
Etoposide Segment by Application
Small Cell Lung Cancer
Testicular Cancer
Etoposide Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Etoposide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Etoposide and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Etoposide.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Etoposide market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Etoposide manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Etoposide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Etoposide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Etoposide for Injection
- Etoposide for Oral Use
Applications
- Small Cell Lung Cancer
- Testicular Cancer
Companies covered
- Teva Pharmaceutical
- Qilu Antibiotics
- Mylan
- China Resources Double Crane Pharmaceutical
- Shyndec Pharmaceutical
- Nippon Kayaku
- KPC Pharmaceuticals
- Gansu Fuzheng
- Accord Healthcare
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Etoposide Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Etoposide Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Etoposide Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Etoposide Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Etoposide Market Dynamics
- 2.1 Etoposide Industry Trends
- 2.2 Etoposide Industry Drivers
- 2.3 Etoposide Industry Opportunities and Challenges
- 2.4 Etoposide Industry Restraints
3 Etoposide Market by Manufacturers
- 3.1 Global Etoposide Revenue by Manufacturers (2021-2026)
- 3.2 Global Etoposide Sales by Manufacturers (2021-2026)
- 3.3 Global Etoposide Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Etoposide Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Etoposide Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Etoposide Manufacturers, Product Type & Application
- 3.7 Global Etoposide Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Etoposide Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Etoposide Players Market Share by Revenue in 2025
- 3.8.3 2025 Etoposide Tier 1, Tier 2, and Tier 3
4 Etoposide Market by Type
- 4.1 Etoposide Type Introduction
- 4.1.1 Etoposide for Injection
- 4.1.2 Etoposide for Oral Use
- 4.2 Global Etoposide Sales by Type
- 4.2.1 Global Etoposide Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Etoposide Sales by Type (2021-2032)
- 4.2.3 Global Etoposide Sales Market Share by Type (2021-2032)
- 4.3 Global Etoposide Revenue by Type
- 4.3.1 Global Etoposide Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Etoposide Revenue by Type (2021-2032)
- 4.3.3 Global Etoposide Revenue Market Share by Type (2021-2032)
5 Etoposide Market by Application
- 5.1 Etoposide Application Introduction
- 5.1.1 Small Cell Lung Cancer
- 5.1.2 Testicular Cancer
- 5.2 Global Etoposide Sales by Application
- 5.2.1 Global Etoposide Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Etoposide Sales by Application (2021-2032)
- 5.2.3 Global Etoposide Sales Market Share by Application (2021-2032)
- 5.3 Global Etoposide Revenue by Application
- 5.3.1 Global Etoposide Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Etoposide Revenue by Application (2021-2032)
- 5.3.3 Global Etoposide Revenue Market Share by Application (2021-2032)
6 Global Etoposide Sales by Region
- 6.1 Global Etoposide Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Etoposide Sales by Region (2021-2032)
- 6.2.1 Global Etoposide Sales by Region (2021-2026)
- 6.2.2 Global Etoposide Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Etoposide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Etoposide Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Etoposide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Etoposide Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Etoposide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Etoposide Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Etoposide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Etoposide Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Etoposide Revenue by Region
- 7.1 Global Etoposide Revenue by Region
- 7.1.1 Global Etoposide Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Etoposide Revenue by Region (2021-2026)
- 7.1.3 Global Etoposide Revenue by Region (2027-2032)
- 7.1.4 Global Etoposide Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Etoposide Revenue (2021-2032)
- 7.2.2 North America Etoposide Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Etoposide Revenue (2021-2032)
- 7.3.2 Europe Etoposide Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Etoposide Revenue (2021-2032)
- 7.4.2 Asia-Pacific Etoposide Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Etoposide Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Etoposide Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Teva Pharmaceutical
- 8.1.1 Teva Pharmaceutical Company Information
- 8.1.2 Teva Pharmaceutical Business Overview
- 8.1.3 Teva Pharmaceutical Etoposide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Teva Pharmaceutical Etoposide Product Portfolio
- 8.1.5 Teva Pharmaceutical Recent Developments
- 8.2 Qilu Antibiotics
- 8.2.1 Qilu Antibiotics Company Information
- 8.2.2 Qilu Antibiotics Business Overview
- 8.2.3 Qilu Antibiotics Etoposide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Qilu Antibiotics Etoposide Product Portfolio
- 8.2.5 Qilu Antibiotics Recent Developments
- 8.3 Mylan
- 8.3.1 Mylan Company Information
- 8.3.2 Mylan Business Overview
- 8.3.3 Mylan Etoposide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Mylan Etoposide Product Portfolio
- 8.3.5 Mylan Recent Developments
- 8.4 China Resources Double Crane Pharmaceutical
- 8.4.1 China Resources Double Crane Pharmaceutical Company Information
- 8.4.2 China Resources Double Crane Pharmaceutical Business Overview
- 8.4.3 China Resources Double Crane Pharmaceutical Etoposide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 China Resources Double Crane Pharmaceutical Etoposide Product Portfolio
- 8.4.5 China Resources Double Crane Pharmaceutical Recent Developments
- 8.5 Shyndec Pharmaceutical
- 8.5.1 Shyndec Pharmaceutical Company Information
- 8.5.2 Shyndec Pharmaceutical Business Overview
- 8.5.3 Shyndec Pharmaceutical Etoposide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Shyndec Pharmaceutical Etoposide Product Portfolio
- 8.5.5 Shyndec Pharmaceutical Recent Developments
- 8.6 Nippon Kayaku
- 8.6.1 Nippon Kayaku Company Information
- 8.6.2 Nippon Kayaku Business Overview
- 8.6.3 Nippon Kayaku Etoposide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Nippon Kayaku Etoposide Product Portfolio
- 8.6.5 Nippon Kayaku Recent Developments
- 8.7 KPC Pharmaceuticals
- 8.7.1 KPC Pharmaceuticals Company Information
- 8.7.2 KPC Pharmaceuticals Business Overview
- 8.7.3 KPC Pharmaceuticals Etoposide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 KPC Pharmaceuticals Etoposide Product Portfolio
- 8.7.5 KPC Pharmaceuticals Recent Developments
- 8.8 Gansu Fuzheng
- 8.8.1 Gansu Fuzheng Company Information
- 8.8.2 Gansu Fuzheng Business Overview
- 8.8.3 Gansu Fuzheng Etoposide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Gansu Fuzheng Etoposide Product Portfolio
- 8.8.5 Gansu Fuzheng Recent Developments
- 8.9 Accord Healthcare
- 8.9.1 Accord Healthcare Company Information
- 8.9.2 Accord Healthcare Business Overview
- 8.9.3 Accord Healthcare Etoposide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Accord Healthcare Etoposide Product Portfolio
- 8.9.5 Accord Healthcare Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Etoposide Value Chain Analysis
- 9.1.1 Etoposide Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Etoposide Production Mode & Process
- 9.2 Etoposide Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Etoposide Distributors
- 9.2.3 Etoposide Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst